Multivariate logistic analyses, restricted to FOLFOX-4-treated patients (as only they were exposed to a pump), showed that pump malfunction was associated with an increased risk of grade 3/4 neutropenia (OR 1.57, 97.5% CI: 1.03–2.38; P =0.00165) and a numerical trend for increased risk of grade 3/4 adverse events of special interest for fluoropyrimidines such as neutropenia and gastrointestinal effects (OR 1.25, 97.5% CI: 0.82–1.92; P =0.2361).
← all excerpts
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial.
1
—
—